One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
MapLight Therapeutics, Inc.
MPLT · NMS · Healthcare · Biotechnology
Current price
$7.98
52-week range
$7.46 - $40.43
Market cap
$443.49M
Balance sheet
Healthy
-30.64x Concerning
Net cash $302.74M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is developing medicines for serious brain and nerve conditions like schizophrenia, Alzheimer's, and Parkinson's. Their main money will eventually come from selling these new drugs once they are approved by regulators. This is important because if their treatments work, they could help many people and become a successful company.
How the company got here
MapLight Therapeutics, Inc., formerly known as Alvarado Therapeutics, Inc., was established in 2018 and is based in Redwood City, California. The company's journey began with a focus on developing treatments for severe neurological and psychiatric conditions. A key turning point was its name change to MapLight Therapeutics in August 2019, signaling a renewed focus and potentially a shift in its strategic direction within the biopharmaceutical landscape. The company operates as a clinical-stage biopharmaceutical firm, meaning it is actively testing its potential drug candidates in human trials.
What it actually does
MapLight Therapeutics is dedicated to creating new medicines for people suffering from difficult central nervous system (CNS) disorders. These are conditions that affect the brain and spinal cord, often leading to significant challenges in daily life. The company's approach involves identifying specific neural circuits (pathways in the brain) that are linked to diseases and then developing targeted therapies to help modulate or correct their function. Their work is focused on developing treatments that can offer relief and improve the quality of life for patients facing these complex conditions.
Drug Development Pipeline
MapLight Therapeutics' core business revolves around its pipeline of potential drug candidates, each targeting different neurological and psychiatric conditions. One key candidate is ML-007C-MA, a combination drug designed to act on specific receptors in the brain (M1/M4 muscarinic agonist) to treat psychosis associated with schizophrenia and Alzheimer's disease. Another is ML-004, aimed at improving social communication and reducing irritability in individuals with autism spectrum disorder. The company is also developing ML-021 for motor deficits in Parkinson's disease, ML-055 for various neuropsychiatric conditions, and ML-009, which targets hyperactivity and agitation by modulating a specific brain receptor (G-protein-coupled receptor 52 positive allosteric modulator).
What management is betting on now
Management at MapLight Therapeutics is primarily focused on advancing its clinical-stage drug candidates through rigorous testing and regulatory approval processes. Their strategy hinges on successfully demonstrating the safety and efficacy of their lead compounds, such as ML-007C-MA for psychosis and ML-004 for autism spectrum disorder, in human trials. By targeting specific neural circuits and developing novel therapeutic approaches, the company aims to address significant unmet medical needs in debilitating CNS disorders. Success in these clinical trials is crucial for the company's future growth and its ability to bring these potential treatments to patients.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-57.99M
FY2024 Q4
$-21.59M
FY2025 Q2
$-34.03M
FY2025 Q3
$-31.82M
FY2025 Q4
$-47.20M
FY2026 Q1
$-51.20M
FY2026 Q2
$-44.89M
Revenue
—
Net income
$-60.19M
Diluted EPS
-1.32
Operating cash flow
$-44.87M
Free cash flow
$-44.89M
Fetching…
Sources
Revenue
—
Net income
$-60.67M
Diluted EPS
-1.34
Operating cash flow
$-51.18M
Free cash flow
$-51.20M
Fetching…
Sources
Revenue
—
Net income
$-79.55M
Diluted EPS
87.06
Operating cash flow
$-46.83M
Free cash flow
$-47.20M
Fetching…
Sources
Revenue
—
Net income
$-29.42M
Diluted EPS
-37.18
Operating cash flow
$-31.79M
Free cash flow
$-31.82M
Fetching…
Sources
Revenue
—
Net income
$-29.85M
Diluted EPS
-39.11
Operating cash flow
$-33.97M
Free cash flow
$-34.03M
Fetching…
Sources
Revenue
—
Net income
$-22.34M
Diluted EPS
-29.33
Operating cash flow
$-25.55M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-21.23M
Diluted EPS
-105.38
Operating cash flow
$-21.49M
Free cash flow
$-21.59M
Fetching…
Sources
Revenue
—
Net income
$-19.02M
Diluted EPS
-25.08
Operating cash flow
$-57.33M
Free cash flow
$-57.99M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $7.98
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $302.7M - more cash than debt. Interest coverage -30.6x.
Net debt
$-302.74M
Interest coverage
-30.64x
MapLight Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
MPLT
BASELINE
MapLight Therapeutics, Inc.
Total debt $1.99M Interest coverage -30.64x This is the baseline the peer rows are being compared against.
Total debt $93.27M Interest coverage -11.92x Neither company has much profit cushion over interest right now.
Total debt $60.42M Interest coverage -12.13x Neither company has much profit cushion over interest right now.
Total debt $22.64M Interest coverage -6.63x Neither company has much profit cushion over interest right now.
Total debt $2.68M Interest coverage -1.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against MPLT
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -111.5% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.33x
P/B
1.04x
P/S
—
EV/EBITDA
-0.31x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-111.5%
ROA
-67.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.01x
Current ratio
16.52x
Quick ratio
15.79x
Total debt
$1.99M
Total cash
$304.72M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-6.25
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-174.67M
Free CF TTM
$-138.61M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—